HEADER TRANSFERASE/TRANSFERASE INHIBITOR 14-NOV-13 4NLD TITLE CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA TITLE 2 POLYMERASE COMPLEX WITH BMS-791325 ALSO KNOWN AS (1AR,12BS)-8- TITLE 3 CYCLOHEXYL-N-(DIMETHYLSULFAMOYL)-11-METHOXY-1A-{[(1R,5S)-3-METHYL-3, TITLE 4 8-DIAZABICYCLO[3.2.1]OCT-8-YL]CARBONYL}-1,1A,2,12B- TITLE 5 TETRAHYDROCYCLOPROPA[D]INDOLO[2,1-A][2]BENZAZEPINE-5-CARBOXAMIDE AND TITLE 6 2-(4-FLUOROPHENYL)-N-METHYL-6-[(METHYLSULFONYL)AMINO]-5-(PROPAN-2- TITLE 7 YLOXY)-1-BENZOFURAN-3-CARBOXAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: RNA-DIRECTED RNA POLYMERASE; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: UNP RESIDUES 2420-2992; COMPND 5 SYNONYM: NS5B, P68; COMPND 6 EC: 2.7.7.48; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HEPATITIS C VIRUS; SOURCE 3 ORGANISM_COMMON: HCV; SOURCE 4 ORGANISM_TAXID: 333284; SOURCE 5 STRAIN: BARTENSCHLAGER; SOURCE 6 GENE: NS5B; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 9 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) STAR; SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PET21B KEYWDS NS5B, POLYMERASE, HCV, HEPATITIS C VIRUS, FINGERS, PALM, THUMB, KEYWDS 2 TRANSFERASE/TRANSFERASE INHIBITOR, POLYMERASE/POLYMERASE INHIBITOR, KEYWDS 3 TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR S.SHERIFF REVDAT 5 03-APR-24 4NLD 1 REMARK REVDAT 4 28-FEB-24 4NLD 1 HETSYN REVDAT 3 29-JUL-20 4NLD 1 COMPND REMARK SEQADV HETNAM REVDAT 3 2 1 SITE REVDAT 2 26-MAR-14 4NLD 1 JRNL REVDAT 1 19-MAR-14 4NLD 0 JRNL AUTH R.G.GENTLES,M.DING,J.A.BENDER,C.P.BERGSTROM,K.GRANT-YOUNG, JRNL AUTH 2 P.HEWAWASAM,T.HUDYMA,S.MARTIN,A.NICKEL,A.REGUEIRO-REN,Y.TU, JRNL AUTH 3 Z.YANG,K.S.YEUNG,X.ZHENG,S.CHAO,J.H.SUN,B.R.BENO,D.M.CAMAC, JRNL AUTH 4 C.H.CHANG,M.GAO,P.E.MORIN,S.SHERIFF,J.TREDUP,J.WAN, JRNL AUTH 5 M.R.WITMER,D.XIE,U.HANUMEGOWDA,J.KNIPE,K.MOSURE,K.S.SANTONE, JRNL AUTH 6 D.D.PARKER,X.ZHUO,J.LEMM,M.LIU,L.PELOSI,K.RIGAT,S.VOSS, JRNL AUTH 7 Y.WANG,Y.K.WANG,R.J.COLONNO,M.GAO,S.B.ROBERTS,Q.GAO,A.NG, JRNL AUTH 8 N.A.MEANWELL,J.F.KADOW JRNL TITL DISCOVERY AND PRECLINICAL CHARACTERIZATION OF THE JRNL TITL 2 CYCLOPROPYLINDOLOBENZAZEPINE BMS-791325, A POTENT ALLOSTERIC JRNL TITL 3 INHIBITOR OF THE HEPATITIS C VIRUS NS5B POLYMERASE. JRNL REF J.MED.CHEM. V. 57 1855 2014 JRNL REFN ISSN 0022-2623 JRNL PMID 24397558 JRNL DOI 10.1021/JM4016894 REMARK 2 REMARK 2 RESOLUTION. 2.75 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER-TNT BUSTER 2.11.4 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.75 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 39.42 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 92.4 REMARK 3 NUMBER OF REFLECTIONS : 21785 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.215 REMARK 3 R VALUE (WORKING SET) : 0.213 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.730 REMARK 3 FREE R VALUE TEST SET COUNT : 1030 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 11 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.75 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.88 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 92.38 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2928 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2453 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2796 REMARK 3 BIN R VALUE (WORKING SET) : 0.2444 REMARK 3 BIN FREE R VALUE : 0.2637 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.51 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 132 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3867 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 136 REMARK 3 SOLVENT ATOMS : 31 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 72.05 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 61.27 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 4.82020 REMARK 3 B22 (A**2) : -12.76960 REMARK 3 B33 (A**2) : 7.94930 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.402 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.498 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.302 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.518 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.306 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.924 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.901 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4158 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 5716 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1431 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 76 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 658 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4158 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 536 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 4708 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.07 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.89 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 18.81 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4NLD COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-DEC-13. REMARK 100 THE DEPOSITION ID IS D_1000083348. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-NOV-06 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 5.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 (DENZO) REMARK 200 DATA SCALING SOFTWARE : HKL-2000 (SCALEPACK) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22091 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.750 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.0 REMARK 200 DATA REDUNDANCY : 5.500 REMARK 200 R MERGE (I) : 0.08100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 18.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.85 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.7 REMARK 200 DATA REDUNDANCY IN SHELL : 5.50 REMARK 200 R MERGE FOR SHELL (I) : 0.49900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NS5B/LIGAND COMPLEX REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.52 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.47 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM SODIUM CITRATE, 1.75 M REMARK 280 (NH4)2SO4, PH 5.6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE REMARK 280 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 36.50000 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 60.30000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 100.75000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 36.50000 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 60.30000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 100.75000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 36.50000 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 60.30000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 100.75000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 36.50000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 60.30000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 100.75000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 0 REMARK 465 SER A 1 REMARK 465 MET A 2 REMARK 465 SER A 3 REMARK 465 TYR A 4 REMARK 465 THR A 5 REMARK 465 TRP A 6 REMARK 465 THR A 7 REMARK 465 GLY A 8 REMARK 465 ALA A 9 REMARK 465 LEU A 10 REMARK 465 ILE A 11 REMARK 465 THR A 12 REMARK 465 PRO A 13 REMARK 465 CYS A 14 REMARK 465 ALA A 15 REMARK 465 ALA A 16 REMARK 465 GLU A 17 REMARK 465 GLU A 18 REMARK 465 THR A 19 REMARK 465 LYS A 20 REMARK 465 LEU A 21 REMARK 465 PRO A 22 REMARK 465 ILE A 23 REMARK 465 ASN A 24 REMARK 465 ALA A 25 REMARK 465 LEU A 26 REMARK 465 SER A 27 REMARK 465 ASN A 28 REMARK 465 SER A 29 REMARK 465 LEU A 30 REMARK 465 LEU A 31 REMARK 465 ARG A 32 REMARK 465 HIS A 33 REMARK 465 HIS A 34 REMARK 465 ASN A 35 REMARK 465 LEU A 36 REMARK 465 VAL A 37 REMARK 465 TYR A 38 REMARK 465 ALA A 39 REMARK 465 THR A 40 REMARK 465 THR A 41 REMARK 465 SER A 42 REMARK 465 ARG A 43 REMARK 465 SER A 44 REMARK 465 ALA A 45 REMARK 465 SER A 46 REMARK 465 LEU A 47 REMARK 465 ARG A 48 REMARK 465 GLN A 49 REMARK 465 LYS A 50 REMARK 465 LYS A 51 REMARK 465 VAL A 52 REMARK 465 THR A 53 REMARK 465 SER A 269 REMARK 465 LYS A 270 REMARK 465 GLY A 271 REMARK 465 GLN A 272 REMARK 465 ASN A 273 REMARK 465 ASP A 559 REMARK 465 ILE A 560 REMARK 465 TYR A 561 REMARK 465 HIS A 562 REMARK 465 SER A 563 REMARK 465 LEU A 564 REMARK 465 SER A 565 REMARK 465 ARG A 566 REMARK 465 ALA A 567 REMARK 465 ARG A 568 REMARK 465 PRO A 569 REMARK 465 ARG A 570 REMARK 465 TRP A 571 REMARK 465 PHE A 572 REMARK 465 MET A 573 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU A 57 CG CD1 CD2 REMARK 470 LYS A 114 CG CD CE NZ REMARK 470 GLU A 131 CG CD OE1 OE2 REMARK 470 LYS A 355 CD CE NZ REMARK 470 ARG A 531 CD NE CZ NH1 NH2 REMARK 470 GLN A 544 CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 55 -125.24 46.03 REMARK 500 ALA A 105 154.77 60.68 REMARK 500 LYS A 106 -60.16 74.48 REMARK 500 LEU A 111 126.61 59.82 REMARK 500 GLU A 131 -31.55 -130.22 REMARK 500 PHE A 145 58.27 -92.29 REMARK 500 THR A 181 -40.51 -132.43 REMARK 500 LEU A 260 -58.38 -128.59 REMARK 500 ILE A 424 -61.94 -101.43 REMARK 500 TYR A 448 -107.87 59.36 REMARK 500 LEU A 536 94.18 77.30 REMARK 500 REMARK 500 REMARK: NULL DBREF 4NLD A 1 573 UNP Q9WMX2 POLG_HCVCO 2420 2992 SEQADV 4NLD MET A 0 UNP Q9WMX2 EXPRESSION TAG SEQRES 1 A 574 MET SER MET SER TYR THR TRP THR GLY ALA LEU ILE THR SEQRES 2 A 574 PRO CYS ALA ALA GLU GLU THR LYS LEU PRO ILE ASN ALA SEQRES 3 A 574 LEU SER ASN SER LEU LEU ARG HIS HIS ASN LEU VAL TYR SEQRES 4 A 574 ALA THR THR SER ARG SER ALA SER LEU ARG GLN LYS LYS SEQRES 5 A 574 VAL THR PHE ASP ARG LEU GLN VAL LEU ASP ASP HIS TYR SEQRES 6 A 574 ARG ASP VAL LEU LYS GLU MET LYS ALA LYS ALA SER THR SEQRES 7 A 574 VAL LYS ALA LYS LEU LEU SER VAL GLU GLU ALA CYS LYS SEQRES 8 A 574 LEU THR PRO PRO HIS SER ALA ARG SER LYS PHE GLY TYR SEQRES 9 A 574 GLY ALA LYS ASP VAL ARG ASN LEU SER SER LYS ALA VAL SEQRES 10 A 574 ASN HIS ILE ARG SER VAL TRP LYS ASP LEU LEU GLU ASP SEQRES 11 A 574 THR GLU THR PRO ILE ASP THR THR ILE MET ALA LYS ASN SEQRES 12 A 574 GLU VAL PHE CYS VAL GLN PRO GLU LYS GLY GLY ARG LYS SEQRES 13 A 574 PRO ALA ARG LEU ILE VAL PHE PRO ASP LEU GLY VAL ARG SEQRES 14 A 574 VAL CYS GLU LYS MET ALA LEU TYR ASP VAL VAL SER THR SEQRES 15 A 574 LEU PRO GLN ALA VAL MET GLY SER SER TYR GLY PHE GLN SEQRES 16 A 574 TYR SER PRO GLY GLN ARG VAL GLU PHE LEU VAL ASN ALA SEQRES 17 A 574 TRP LYS ALA LYS LYS CYS PRO MET GLY PHE ALA TYR ASP SEQRES 18 A 574 THR ARG CYS PHE ASP SER THR VAL THR GLU ASN ASP ILE SEQRES 19 A 574 ARG VAL GLU GLU SER ILE TYR GLN CYS CYS ASP LEU ALA SEQRES 20 A 574 PRO GLU ALA ARG GLN ALA ILE ARG SER LEU THR GLU ARG SEQRES 21 A 574 LEU TYR ILE GLY GLY PRO LEU THR ASN SER LYS GLY GLN SEQRES 22 A 574 ASN CYS GLY TYR ARG ARG CYS ARG ALA SER GLY VAL LEU SEQRES 23 A 574 THR THR SER CYS GLY ASN THR LEU THR CYS TYR LEU LYS SEQRES 24 A 574 ALA ALA ALA ALA CYS ARG ALA ALA LYS LEU GLN ASP CYS SEQRES 25 A 574 THR MET LEU VAL CYS GLY ASP ASP LEU VAL VAL ILE CYS SEQRES 26 A 574 GLU SER ALA GLY THR GLN GLU ASP GLU ALA SER LEU ARG SEQRES 27 A 574 ALA PHE THR GLU ALA MET THR ARG TYR SER ALA PRO PRO SEQRES 28 A 574 GLY ASP PRO PRO LYS PRO GLU TYR ASP LEU GLU LEU ILE SEQRES 29 A 574 THR SER CYS SER SER ASN VAL SER VAL ALA HIS ASP ALA SEQRES 30 A 574 SER GLY LYS ARG VAL TYR TYR LEU THR ARG ASP PRO THR SEQRES 31 A 574 THR PRO LEU ALA ARG ALA ALA TRP GLU THR ALA ARG HIS SEQRES 32 A 574 THR PRO VAL ASN SER TRP LEU GLY ASN ILE ILE MET TYR SEQRES 33 A 574 ALA PRO THR LEU TRP ALA ARG MET ILE LEU MET THR HIS SEQRES 34 A 574 PHE PHE SER ILE LEU LEU ALA GLN GLU GLN LEU GLU LYS SEQRES 35 A 574 ALA LEU ASP CYS GLN ILE TYR GLY ALA CYS TYR SER ILE SEQRES 36 A 574 GLU PRO LEU ASP LEU PRO GLN ILE ILE GLN ARG LEU HIS SEQRES 37 A 574 GLY LEU SER ALA PHE SER LEU HIS SER TYR SER PRO GLY SEQRES 38 A 574 GLU ILE ASN ARG VAL ALA SER CYS LEU ARG LYS LEU GLY SEQRES 39 A 574 VAL PRO PRO LEU ARG VAL TRP ARG HIS ARG ALA ARG SER SEQRES 40 A 574 VAL ARG ALA ARG LEU LEU SER GLN GLY GLY ARG ALA ALA SEQRES 41 A 574 THR CYS GLY LYS TYR LEU PHE ASN TRP ALA VAL ARG THR SEQRES 42 A 574 LYS LEU LYS LEU THR PRO ILE PRO ALA ALA SER GLN LEU SEQRES 43 A 574 ASP LEU SER SER TRP PHE VAL ALA GLY TYR SER GLY GLY SEQRES 44 A 574 ASP ILE TYR HIS SER LEU SER ARG ALA ARG PRO ARG TRP SEQRES 45 A 574 PHE MET HET 2N7 A 601 92 HET 2N5 A 602 50 HET SO4 A 603 5 HET SO4 A 604 5 HET SO4 A 605 5 HET SO4 A 606 5 HET BOG A 607 20 HET BOG A 608 20 HETNAM 2N7 (1AR,12BS)-8-CYCLOHEXYL-N-(DIMETHYLSULFAMOYL)-11- HETNAM 2 2N7 METHOXY-1A-{[(1R,5S)-3-METHYL-3,8- HETNAM 3 2N7 DIAZABICYCLO[3.2.1]OCT-8-YL]CARBONYL}-1,1A,2,12B- HETNAM 4 2N7 TETRAHYDROCYCLOPROPA[D]INDOLO[2,1-A][2]BENZAZEPINE-5- HETNAM 5 2N7 CARBOXAMIDE HETNAM 2N5 2-(4-FLUOROPHENYL)-N-METHYL-6-[(METHYLSULFONYL)AMINO]- HETNAM 2 2N5 5-(PROPAN-2-YLOXY)-1-BENZOFURAN-3-CARBOXAMIDE HETNAM SO4 SULFATE ION HETNAM BOG OCTYL BETA-D-GLUCOPYRANOSIDE HETSYN BOG BETA-OCTYLGLUCOSIDE; OCTYL BETA-D-GLUCOSIDE; OCTYL D- HETSYN 2 BOG GLUCOSIDE; OCTYL GLUCOSIDE FORMUL 2 2N7 C36 H45 N5 O5 S FORMUL 3 2N5 C20 H21 F N2 O5 S FORMUL 4 SO4 4(O4 S 2-) FORMUL 8 BOG 2(C14 H28 O6) FORMUL 10 HOH *31(H2 O) HELIX 1 1 ASP A 61 SER A 76 1 16 HELIX 2 2 SER A 84 LEU A 91 1 8 HELIX 3 3 SER A 112 ASP A 129 1 18 HELIX 4 4 ASP A 164 SER A 180 1 17 HELIX 5 5 THR A 181 GLY A 188 1 8 HELIX 6 6 SER A 189 TYR A 195 5 7 HELIX 7 7 SER A 196 LYS A 211 1 16 HELIX 8 8 THR A 229 GLN A 241 1 13 HELIX 9 9 ALA A 246 LEU A 260 1 15 HELIX 10 10 GLY A 283 ALA A 306 1 24 HELIX 11 11 GLY A 328 TYR A 346 1 19 HELIX 12 12 ASP A 359 ILE A 363 5 5 HELIX 13 13 PRO A 388 ARG A 401 1 14 HELIX 14 14 ASN A 406 ALA A 416 1 11 HELIX 15 15 THR A 418 ILE A 424 1 7 HELIX 16 16 ILE A 424 GLU A 437 1 14 HELIX 17 17 GLU A 455 LEU A 457 5 3 HELIX 18 18 ASP A 458 GLY A 468 1 11 HELIX 19 19 LEU A 469 SER A 473 5 5 HELIX 20 20 SER A 478 GLY A 493 1 16 HELIX 21 21 PRO A 496 GLN A 514 1 19 HELIX 22 22 GLY A 515 PHE A 526 1 12 HELIX 23 23 ASN A 527 VAL A 530 5 4 HELIX 24 24 ALA A 541 ASP A 546 1 6 HELIX 25 25 SER A 548 VAL A 552 5 5 SHEET 1 A 4 ALA A 157 PRO A 163 0 SHEET 2 A 4 THR A 136 ASN A 142 -1 N LYS A 141 O ARG A 158 SHEET 3 A 4 GLY A 264 THR A 267 1 O THR A 267 N THR A 136 SHEET 4 A 4 TYR A 276 ARG A 277 -1 O ARG A 277 N GLY A 264 SHEET 1 B 3 PRO A 214 ASP A 220 0 SHEET 2 B 3 ASP A 319 GLU A 325 -1 O CYS A 324 N MET A 215 SHEET 3 B 3 GLN A 309 CYS A 316 -1 N CYS A 316 O ASP A 319 SHEET 1 C 2 ASN A 369 HIS A 374 0 SHEET 2 C 2 ARG A 380 THR A 385 -1 O VAL A 381 N ALA A 373 SHEET 1 D 2 LEU A 443 GLN A 446 0 SHEET 2 D 2 CYS A 451 ILE A 454 -1 O ILE A 454 N LEU A 443 CRYST1 73.000 120.600 201.500 90.00 90.00 90.00 I 2 2 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013699 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008292 0.000000 0.00000 SCALE3 0.000000 0.000000 0.004963 0.00000